Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for Pfizer (PFE) through the VizualStocks API.
Worldwide revenue from Abrysvo, Pfizer's vaccine for preventing lower respiratory tract disease caused by respiratory syncytial virus (RSV). Its approved uses include vaccination of older or at-risk adults and maternal immunization to protect infants, depending on the market and period.
abrysvoRevenueWorldwide Oncology revenue excluding Ibrance, following the issuer's disclosed therapeutic-area composition and published historical recasts. This broad remainder includes other individually named oncology products and is not Pfizer's narrower printed All other Oncology row. Before Ibrance's 2015 launch, the directly reported Global Oncology total represents this scope.
allOtherOncologyRevenueWorldwide Primary Care revenue excluding the separately charted Eliquis, Paxlovid, Prevnar family, Comirnaty, Nurtec ODT/Vydura and Abrysvo products as applicable. This is a broad remainder, not Pfizer's narrower All other Primary Care row. Historical composition follows the issuer's Internal Medicine/Vaccines grouping and published commercial-structure recasts.
allOtherPrimaryCareRevenueWorldwide Specialty Care revenue excluding the Vyndaqel family and Xeljanz. This broad remainder includes other individually named specialty-care products and is not Pfizer's narrower All other Specialty Care row. Published historical recasts reflect the 2022 therapeutic-area grouping and 2026 Hospital and Biosimilars separation where available.
allOtherSpecialtyCareRevenueRevenue of Pfizer's issuer-defined Biopharma business, excluding separately reported Pfizer CentreOne/other business activities where applicable. Historical comparisons follow the disclosed commercial structure and published recasts, including the late-2021 PC1 separation; this is not a uniform all-pharmaceutical-products subtotal.
biopharmaRevenueRevenue from Pfizer CentreOne, Pfizer's contract development and manufacturing operation, including third-party manufacturing, active pharmaceutical ingredient sales and supply agreements with legacy Pfizer businesses or partnerships. The older Business Innovation label also included Pfizer Ignite, whose wind-down revenue was immaterial and is included where Pfizer recast it.
businessInnovationPfizerCentreOneRevenuePfizer's worldwide Comirnaty revenue, including direct product sales and alliance revenue on the issuer's reported basis. This is Pfizer-recognized revenue, not combined Pfizer/BioNTech end-market sales; product deductions and returns are reflected in the reported amounts.
comirnatyDirectSalesAndAllianceRevenueRevenue in international Developed Markets under Pfizer's post-2023 geographic presentation, excluding the U.S. and including Central Europe and the Balkans. Published historical comparisons use that classification. It is not the older U.S.-inclusive Developed Markets glossary definition or a simple sum of the two retired developed-region fields.
developedMarketsRevenuePfizer's worldwide Eliquis alliance revenue and direct product sales for the reported period. This is not total Eliquis end-market sales or Pfizer's broader multi-product Alliance revenues subtotal.
eliquisAllianceRevenueAndDirectSalesRevenue from Pfizer's post-2023 international Emerging Markets group, which excludes the United States and the countries assigned to international Developed Markets. It covers markets across Latin America, Asia, the Middle East and Africa under Pfizer's current classification and is separate from the retired pre-2024 series.
emergingMarketsRevenueAfterFiscalYear2023ReportingWorldwide revenue from Ibrance, Pfizer's CDK4/6 inhibitor used primarily to treat hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. The figure represents Pfizer-recognized product revenue across U.S. and international markets.
ibranceRevenueWorldwide revenue from rimegepant, sold by Pfizer as Nurtec ODT in the United States and Vydura in international markets. The medicine is used for acute migraine treatment and prevention of episodic migraine.
nurtecOdtVyduraRevenueRevenue from Pfizer's explicitly reported Other product line when that residual appears in the issuer's product table. It is a legacy source field, not a calculated difference between total revenue and the individually displayed products, and recent periods are largely blank or zero.
otherRevenueTotal international revenue outside the United States, as reported by Pfizer. This legacy key overlaps the other total-international alias and the disclosed international subregions; it is not an additional Other region to add to Developed and Emerging Markets. International operations follow Pfizer's consolidation calendar.
otherRevenueByGeographyTotal international revenue outside the United States, as reported by Pfizer. This legacy key overlaps the other total-international alias and the disclosed international subregions; it is not an additional Other region to add to Developed and Emerging Markets. International operations follow Pfizer's consolidation calendar.
otherRevenuesByGeographyLegacy alternate source field for Pfizer's reported Other product revenue line. It overlaps OtherRevenue rather than representing a separate business, and its recent values are largely blank or zero, so the two fields should not be added together.
othersRevenuePfizer's worldwide reported Paxlovid revenue, including recognized returns, contractual revisions and subsequent true-ups. Negative reported revenue is retained where disclosed and is not replaced by gross sales or treatment-course volumes.
paxlovidRevenueWorldwide revenue from Pfizer's Prevnar family of pneumococcal conjugate vaccines under the post-2023 reporting series, including Prevnar 20 and other family formulations reported for the period. The vaccines help prevent pneumonia, invasive pneumococcal disease and certain ear infections caused by Streptococcus pneumoniae.
prevnarFamilyRevenueAfterFiscalYear2023ReportingPfizer's legacy worldwide Prevnar/Prevenar family revenue series through FY2023. The family includes Prevnar 13 and, as introduced and disclosed, Prevnar 20; it is not a uniform Prevnar-13-only series. The post-FY2023 family has a separately registered metric.
prevnarRevenueTotal revenue from Biopharma, Pfizer's main reportable segment for discovering, manufacturing, marketing and selling medicines and vaccines worldwide, excluding Pfizer CentreOne and other separately reported activities. This raw metric overlaps BiopharmaRevenue rather than representing an additional revenue category.
totalBiopharmaRevenuePfizer's reported revenue attributable to the United States for the issuer's fiscal period, including applicable published historical recasts. Geographic revenue follows the issuer's consolidated reporting basis rather than a separately imposed calendar-quarter convention.
unitedStatesRevenuePfizer's worldwide reported Vyndaqel family revenue, including Vyndamax in the U.S. and Vynmac in Japan where included in the issuer's family disclosure. Earlier periods retain the product scope actually reported; the family is not limited to U.S. sales.
vyndaqelRevenueWorldwide revenue from Xeljanz, Pfizer's oral JAK inhibitor for immune-mediated diseases including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, juvenile idiopathic arthritis and ankylosing spondylitis. The metric captures Pfizer-recognized product revenue across approved indications and markets.
xeljanzRevenueRevenue in Pfizer's historical Developed Europe grouping, including Western Europe, Scandinavian countries and Finland. This legacy geographic series is distinct from the later international Developed Markets classification, which also includes additional countries and regions.
developedEuropeRevenueRevenue in Pfizer's historical Developed Rest of World grouping, including Japan, Canada, South Korea, Australia and New Zealand. This excludes the separately reported U.S. and Developed Europe and is distinct from the later international Developed Markets series.
developedRestOfWorldRevenueRevenue in Pfizer's legacy Emerging Markets country classification, including Central Europe and other countries later reclassified. This series is distinct from the separately registered post-FY2023 Emerging Markets definition; the two are not a continuous uniform geographic series.
emergingMarketsRevenue